NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Intercure Ltd. INCR
6 fiscal years on record · ILS · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
ILS 238.8M
▼ 32.8% vs FY2023
EPS · FY24
ILS -1.48
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-15.9%
Net margin · FY24
-28.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
ILS 238.8M
Revenue, FY2024 · full 6-year series below
Revenue
Net income
The company lost 28 cents on every revenue dollar this year.
Per share
ILS -1.48
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-15.9%
Return on equity, FY2024
ROE
Operating margin-28.1%
Net margin-28.4%
Return on assets-8.8%
Each ILS of equity lost 16 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+93.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.8%
+93.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
ILS 762.6M
total assets, end of FY2024
Total assetsILS 762.6M
EquityILS 397.0M
CashILS 78.3M
Gross debtILS 183.0M
Net debtILS 104.7M
Current ratio1.73×
Net debt stands at 26% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · ILS
Metric
2024
2023
2022
2021
2020
2019
Revenue ILS B
0.2
0.4
0.4
0.2
0.1
0.0
Operating income ILS B
−0.1
−0.0
0.1
0.0
−0.0
−0.0
EBITDA ILS B
·
·
·
·
·
·
Income tax ILS B
−0.0
0.0
0.0
0.0
−0.0
−0.0
Net income ILS B
−0.1
−0.1
0.0
0.0
−0.0
−0.0
EPS, diluted ILS
−1.48
−1.36
0.99
0.11
−1.42
−0.25
Dividend / sh ILS
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−15.9
−13.0
9.4
1.3
−13.6
·
Shares out B
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
17 of 23
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 5 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed